Nuzenio

Innovent Biologics

Innovent Biologics news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 9 latest news signals 6 publisher sources 100/100 entity strength

Latest news

Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China - Yahoo Finance SingaporeYahoo Finance Singapore · Mon, 10 Aug 2026 00:00:00 GMTInnovent Doses First Patient in Phase 3 Trial of IBI363 for Advanced Colorectal Cancer - BioPharma APACBioPharma APAC · Sat, 08 Aug 2026 16:11:09 GMTInnovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2a-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China - marketscreener.commarketscreener.com · Thu, 06 Aug 2026 02:05:27 GMTInnovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China - Banning Record GazetteBanning Record Gazette · Thu, 06 Aug 2026 00:00:00 GMTInnovent Biologics' Product Revenue Surges 60% in Q2 - MoomooMoomoo · Wed, 05 Aug 2026 03:08:06 GMTHKEX Announcement Insights | Innovent Bio's product revenue exceeded RMB 8.2 billion in the first half of the year, an increase of over 55% year-on-year - MoomooMoomoo · Wed, 05 Aug 2026 00:59:22 GMTInnovent Biologics: Strong Growth in Biomedicine Business Supported Revenue >1801.HK - MoomooMoomoo · Wed, 05 Aug 2026 00:17:00 GMTInnovent Biologics, Inc. Reports Product Revenue Results for the Second Quarter and First Half of 2026 - marketscreener.commarketscreener.com · Wed, 05 Aug 2026 00:01:00 GMT

Timeline

Mon, 10 Aug 2026 00:00:00 GMTInnovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China - Yahoo Finance Singapore
Sat, 08 Aug 2026 16:11:09 GMTInnovent Doses First Patient in Phase 3 Trial of IBI363 for Advanced Colorectal Cancer - BioPharma APAC
Thu, 06 Aug 2026 02:05:27 GMTInnovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2a-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China - marketscreener.com
Thu, 06 Aug 2026 00:00:00 GMTInnovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China - Banning Record Gazette
Wed, 05 Aug 2026 03:08:06 GMTInnovent Biologics' Product Revenue Surges 60% in Q2 - Moomoo
Wed, 05 Aug 2026 00:59:22 GMTHKEX Announcement Insights | Innovent Bio's product revenue exceeded RMB 8.2 billion in the first half of the year, an increase of over 55% year-on-year - Moomoo

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Innovent Biologics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

6 distinct publisher/source names are currently connected to this entity page.